All In MedTech

FDA Clearance Tracker · P150031-S068

Vercise Genus DBS System, Vercise Gevia DBS System, Vercise PC DBS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 14, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 14, 2024

Approved

Time to decision

161 days

Received Dec 5, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150031-S068
Device name
Vercise Genus DBS System, Vercise Gevia DBS System, Vercise PC DBS System
Applicant location
Valencia, CA
Received
Dec 5, 2023
Decided
May 14, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150031

Device type

Device class
Class III

Every decision under product code NHL

FDA's approval statement

As written in FDA's record.

This updated software version only includes the enabling of the DBS Illumina 3D programming feature. All other VNN5 software functions and controls in place for programming the stimulation parameters into the implanted device and for delivering the stimulation via the implanted electrodes remain the same as the previously approved software version. The DBS Illumina 3D programming feature does not replace the need for clinical judgment in determining and finalizing the stimulation parameters that will be clinically effective for the patient, which remains the same as the previously approved software version. The device labeling has been updated with the following changes:- The VNN5 Programming Manual was updated to include the new VNN5 software version number and include instructions specific to the use of the DBS Illumina 3D programming feature.- The Clinician Programmer (CP) Software Installation Guide was updated to remove any specific mention of VNN5, thereby making the instructions more general to installing any software that will be used with the Clinician Programmer.- The DBS Reference Guide was updated to include the new VNN5 software version number and updating the document reference for the new CP Software Installation Guide.- A new Virtual Label was created for VNN5.0.1 to reflect the new software version number.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.